Citius Oncology recorded $5.6 million in net revenue from LYMPHIR during its first launch quarter, achieving approximately 80% gross margins. The company advanced 83% of target accounts to formulary inclusion or active review, secured coverage for nearly 100% of commercial lives, and reported no reimbursement denials, with major academic centers shifting patients to community infusion centers.

Subsequent to quarter end, Citius Oncology raised up to $36.5 million in combined debt and equity financing, including $11.5 million from warrant exercises and a $10 million initial tranche of a $25 million loan facility. These proceeds will fund completion of the commercial field force buildout by mid-summer to accelerate physician engagement and market penetration.

On April 29, 2026, Citius Oncology initiated its first LYMPHIR shipments to Europe through Uniphar, making the therapy available via Named Patient Programs across 19 markets in Southern Europe, the Middle East, and additional European territories. This marks the start of broader global distribution efforts.

Preliminary topline data from two investigator-initiated Phase 1 studies demonstrate LYMPHIR’s potential in combination regimens with pembrolizumab for gynecologic cancers and prior to CD19-directed CAR-T therapy in relapsed or refractory DLBCL. The company also continues FDA engagement on Mino-Lok and Halo-Lido, advancing its critical care pipeline.